0
Original Research: COPD |

The Complex Relationship of Serum Adiponectin to COPD OutcomesCOPD and Adiponectin

Ho Il Yoon, MD, PhD; Yuexin Li, MD; S. F. Paul Man, MD, FCCP; Donald Tashkin, MD; Robert A. Wise, MD, FCCP; John E. Connett, PhD; Nicholas A. Anthonisen, MD, PhD; Andrew Churg, MD; Joanne L. Wright, MD; Don D. Sin, MD, FCCP
Author and Funding Information

From the University of British Columbia James Hogg Research Center and the Providence Heart and Lung Institute at St. Paul’s Hospital (Drs Yoon, Li, Man, and Sin), Vancouver, BC, Canada; the Division of Pulmonary and Critical Care Medicine (Dr Yoon), Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea; the Department of Medicine, Pulmonary Division (Dr Yoon), and the Department of Pathology (Drs Churg and Wright), University of British Columbia, Vancouver, BC, Canada; the University of California at Los Angeles School of Medicine (Dr Tashkin), Los Angeles, CA; the Johns Hopkins University School of Medicine (Dr Wise), Baltimore, MD; the University of Minnesota School of Public Health (Dr Connett), Minneapolis, MN; and the Department of Medicine (Dr Anthonisen), University of Manitoba, Winnipeg, MB, Canada.

Correspondence to: Don D. Sin, MD, FCCP, St. Paul’s Hospital, 1081 Burrard St, Vancouver, BC, V6Z 1Y6, Canada; e-mail: don.Sin@hli.ubc.ca


For editorial comment see page 820

Funding/Support: This work was supported by Canadian Institutes of Health Research.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2012;142(4):893-899. doi:10.1378/chest.11-2173
Text Size: A A A
Published online

Background:  COPD is a chronic inflammatory disorder with high risk of cardiovascular morbidity and mortality. Adiponectin is a hormone that has antiinflammatory, antidiabetic, and antiatherogenic activities. We investigated the relationship of serum adiponectin to health outcomes in COPD.

Methods:  We measured adiponectin levels in serum samples from participants of the Lung Health Study, who were smokers with mild to moderate airflow limitation. We determined the relationship of serum adiponectin to hospitalization and mortality using a Cox proportional hazards model and to baseline lung function measurements and bronchial reactivity using multiple regression methods.

Results:  Serum adiponectin concentrations were inversely related to hospitalizations and mortality from coronary heart disease (hazard ratio [HR], 0.73; 95% CI, 0.62-0.86) and to cardiovascular disease (HR, 0.83; 95% CI, 0.73-0.94) and positively related to deaths from respiratory causes (HR, 2.09; 95% CI, 1.41-3.11). However, serum adiponectin concentrations were not significantly related to total mortality (HR, 1.10; 95% CI, 0.93-1.29) or cancer-related mortality (HR, 1.11; 95% CI, 0.92-1.34). Serum adiponectin concentrations were significantly related to increased bronchial reactivity and an accelerated decline in lung function (both P < .0001). Smoking status had no material influence on serum adiponectin concentrations.

Conclusions:  Adiponectin is a complex serum biomarker in COPD that is associated with decreased risk of cardiovascular events but increased risk of respiratory mortality. Because serum adiponectin is not significantly influenced by smoking status, it is a very promising biomarker of cardiovascular outcomes in COPD.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543